Clinical Trials

NCT Number: NCT03860272 Phase: Phase 1 Trial Summary: This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel fragment crystallizable (Fc)-engineere – clinicaltrials.gov for more information and locations and locations Clinicaltrials.gov Trial Sponsor(s): Agenus Inc. Acronym:

NCT Number: NCT05679388 Phase: Phase 1 Trial Summary: Researchers leading this study hope to learn about the safety of combining the study drug relugolix with another study drug called itraconazole or ritonavir in prostate cancer. Thi – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Chicago Acronym:

NCT Number: NCT05764330 Phase: NA Trial Summary: This clinical trial examines weight loss interventions in reducing cancer progression in prostate cancer patients under active surveillance. Intensive lifestyle interventions that – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Roswell Park Cancer Institute Acronym:

NCT Number: NCT05751434 Phase: Phase 2 Trial Summary: The purpose of this study is to find out the effects of exercise therapy on indicators of prostate cancer in people with low-risk prostate cancer who are on active surveillance. Th – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Memorial Sloan Kettering Cancer Center Acronym:

NCT Number: NCT05722288 Phase: PHASE2 Trial Summary: This phase II trial studies how well time-restricted eating works in reducing side effects of radiation or chemoradiation side effects when compared to nutritional counseling among – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): City of Hope Medical Center Acronym:

NCT Number: NCT05605522 Phase: Phase 1 Trial Summary: This is a first-in-human Phase 1 clinical trial designed to investigate the safety, tolerability, pharmacokinetics, and biodistribution of [225Ac]-FPI-2059 and [111In]-FPI-2058 – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Fusion Pharmaceuticals Inc. Acronym:

NCT Number: NCT05629494 Phase: Phase 4 Trial Summary: Prostate cancer is the most frequently diagnosed cancer in men in the Unites States. Nearly 1 million prostate biopsy procedures are performed in the United States annually and ele – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Albany Medical College Acronym: ADAPT-PSA

NCT Number: NCT05608694 Phase: Not Applicable Trial Summary: The purpose of this study is to determine whether or not Magnetic Resonance Images (MRI) will identify high-grade cancers earlier and more frequently in men at high risk of develop – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Chicago Acronym:

NCT Number: NCT05586360 Phase: Phase 2 Trial Summary: This study will evaluate whether simvastatin reduces intraprostatic immunosuppressive microenvironment through YAP-mediated T-reg dysfunction, and increases intraprostatic anti-tum – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Medical University of South Carolina Acronym:

NCT Number: NCT05526248 Phase: Phase 2 Trial Summary: Researchers are looking for a better way to treat men who have biochemically recurrent hormone-naive – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Bayer Acronym: ARAMON